Drug General Information
Drug ID
D08FUR
Drug Name
IMU-838
Synonyms
Vidofludimus; 717824-30-1; 4SC-101; SC12267; UNII-8Y1PJ3VG81; SC 12267; CHEMBL197194; 8Y1PJ3VG81; Vidofludimus(4SC-101; SC12267); Vidofludimus [INN]; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; IMU-838; DTXSID50431325; HMS3740I15; AOB87354; BCP14555; ZINC14960644; s7262; AK; Vidofludimus
Drug Type
Small molecular drug
Indication Coronavirus Disease 2019 (COVID-19) Phase 2/3 [1]
Therapeutic Class
Antiviral Agents
Structure
Download
2D MOL

3D MOL

Formula
C20H18FNO4
InChIKey
XPRDUGXOWVXZLL-UHFFFAOYSA-N
PubChem Compound ID
Target
Target(s) HUMAN dihydroorotate dehydrogenase (DHODH) Target Info Inhibitor [2]
IMU-838 is a small molecule dihydroorotate dehydrogenase (DHODH) inhibitor, a key enzyme of pyrimidine de novo biosynthesis. Inhibiton of DHODH by IMU-838 suppresses metabolically activate T and B immune cells experience metabolic stress, and the release of Th1 and Th17 key cytokines including IL-17A, IL-17F and IFNg, thereby reducing inflammation in COVID-19. IMU-838 has successfully demonstrated preclinical activity against SARS-CoV-2. Specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19.
References
1 ClinicalTrials.gov (NCT04379271) A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19). U.S. National Institutes of Health.
2 IMU-838 Targeting DHODH

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.